Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens , including a platinum doublet , were randomly assigned at a @:@ ratio to receive erlotinib @ mg daily plus oral tivantinib @ mg twice daily ( E + T ) or erlotinib plus placebo ( E + P ) until disease progression .